The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance.
The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance.
复制标题
DOI:
10.1159/000515731
复制
发表时间:
2020
影响因子:
3.2
通讯作者:
Bauer AJ
中科院分区:
文献类型:
--
作者:
Baran JA;Tsai SD;Isaza A;Brodeur GM;MacFarland SP;Zelley K;Adams DM;Franco AT;Bauer AJ
PTEN Hamartoma Tumor Syndrome (PHTS) comprises a collection of clinical features characterized by constitutional variants in PTEN. Several guidelines recommend thyroid screening beginning in pediatric age at the time of PHTS diagnosis; however, the benefit of early surveillance has not been well defined. We conducted a retrospective investigation of patients followed at the Children’s Hospital of Philadelphia with a diagnosis of PHTS between January 2003 and June 2019. In total, 81 patients under 19 years of age were identified. The most common clinical feature at presentation was macrocephaly (85.1%) followed by impaired development (42.0%), skin/oral lesions (30.9%), and autism spectrum disorder (27.2%). A total of 58 of 81 patients underwent thyroid surveillance, with 30 patients (51.7%) found to have a nodule(s). Ultimately, 16 patients underwent thyroidectomy, with 7.4% (6/81) diagnosed with thyroid cancer. All thyroid cancer patients were older than 10 years of age at diagnosis, and all displayed low-invasive behavior. Of the patients younger than 10 years at the time of thyroid ultrasound (US) surveillance, 71.4% (15/21) had a normal US. The remaining six patients had thyroid nodules, including four undergoing thyroid surgery with benign histology. Patients with macrocephaly, impaired cognitive development and thyroid nodules and/or early onset gastrointestinal (GI) polyps should undergo constitutional testing for PHTS. There does not appear to be a clinical advantage to initiating thyroid US surveillance before 10 years of age. In PHTS patients with a normal physical exam, thyroid US surveillance can be delayed until 10 years of age.
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-11-2283
发表时间:
2012-01-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Tan MH;Mester JL;Ngeow J;Rybicki LA;Orloff MS;Eng C
通讯作者:
Eng C
DOI:
10.4103/0300-1652.110033
发表时间:
2013-03
期刊:
Nigerian medical journal : journal of the Nigeria Medical Association
影响因子:
--
作者:
Abdulkareem IH;Blair M
通讯作者:
Blair M
DOI:
10.1038/s41431-020-0651-7
发表时间:
2020-10
期刊:
European journal of human genetics : EJHG
影响因子:
--
作者:
Tischkowitz M;Colas C;Pouwels S;Hoogerbrugge N;PHTS Guideline Development Group;European Reference Network GENTURIS
通讯作者:
European Reference Network GENTURIS
DOI:
10.6004/jnccn.2017.0003
发表时间:
2017-01-01
影响因子:
13.4
作者:
Daly, Mary B.;Pilarski, Robert;Darlow, Susan
通讯作者:
Darlow, Susan
影响因子:
4
作者:
Lachlan, K. L.;Lucassen, A. M.;Temple, I. K.
通讯作者:
Temple, I. K.